{ Comments on this entry are closed }
A new regression method for predicting likelihood of target mRNA down-regulation from sequence and structure features in microRNA/mRNA predicted target sites.
MirSVR is a new machine learning method for ranking microRNA target sites by a down-regulation score. The algorithm trains a regression model on sequence and contextual features extracted from miRanda-predicted target sites. In a large-scale evaluation, miRanda-mirSVR is competitive with other target prediction methods in identifying target genes and predicting the extent of their downregulation at the mRNA or protein levels. Importantly, the method identifies a significant number of experimentally determined non-canonical and non-conserved sites.
mirSVR scores are available at www.microRNA.org.
Betel D, Koppal A, Agius P, Sander C, Leslie C. (2010) Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biology 11, R90. [article]
{ 0 comments }
Rosetta Genomics to Host Second Quarter 2010 Conference Call on Wednesday, September 8, 2010
REHOVOT, Israel & PHILADELPHIA, Sep 02, 2010 (BUSINESS WIRE) – Rosetta Genomics, Ltd. , a leading developer and provider of microRNA-based molecular diagnostic tests, today announced that the Company will release financial results for the three and six months ended June 30, 2010, after the market closes on Tuesday, September 7, 2010. (read more…)
Regulus Therapeutics Announces U.S. Allowance of a Key Tuschl III Patent Covering miR-155
LA JOLLA, Calif., Aug 10, 2010 (BUSINESS WIRE) – Third Allowance from the Tuschl III IP Estate Bolsters Leadership by Regulus in the Field of microRNA Therapeutics – Regulus Therapeutics Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed claims in a patent application (US Serial No. 12/550,579) derived from the “Tuschl III” patent series. The allowed claims relate to human microRNA miR-155, a microRNA that is a potential target for immuno-inflammatory indications, and a lead program of the Regulus-GSK Strategic Alliance. The strategic alliance with GSK was formed in 2008 to focus on developing microRNA therapeutics for the treatment of immuno-inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. (read more… )
Compendia Bioscience Awarded $1.3 Million in SBIR Fast Track Funds
ANN ARBOR, Mich., Aug 31, 2010 (PRNewswire ) – Compendia Bioscience, Inc. today announced the award of $1.3 million in SBIR Fast Track funds to incorporate micro-RNA data and analyses into the Oncomine platform. Cancer is a highly complex disease in which all of the causes and effects are not well understood. In recent years a new type of non-coding RNA molecule — micro-RNA — has been identified as an important contributor to cancer development, progression, and metastasis, creating a need for cancer researchers to easily access and query this new data type. Despite the growing accumulation of micro-RNA profiling data in a range of cancer-related studies, it is nearly impossible for a cancer biologist to survey the differential expression of an individual micro-RNA or micro-RNA signature across all published datasets, or to integrate knowledge about micro-RNA expression patterns with other relevant biological phenomena such as gene expression, copy number, and mutation data. (read more… )
Jefferson Receive $3 Million NIH Grant to Study Platelets
PHILADELPHIA , Aug 27, 2010 (Newswise) – Scientists at Jefferson Medical College have received a four-year, $3 million National Institutes of Health grant funded by the National Heart, Lung and Blood Institute to study variations of platelet function, specifically, the genetics of platelet gene expression. The study aims to find data that can be translated into novel therapeutic strategies and develop better predictors of cardiovascular disease. The study will focus primarily on looking at platelet microRNA. MicroRNA’s modify gene expression in all tissues, but little is known about how they function in platelets. (read more… )
{ 0 comments }
Loading ...